aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
aTyr Pharma (LIFE) Misses Q2 EPS by 13c
August 10, 2021 4:25 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.64), $0.13 worse than the analyst estimate of ($0.51).
Cash, cash equivalents and investments as of June 30, 2021 were $44.1 million.
We recently completed the last subject visit in our Phase 1b/2a proof-of-concept study of our lead therapeutic candidate,... More



